These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 1387797)

  • 41. Effects of nicorandil, an antianginal potassium channel opener, on left ventricular systolic and diastolic function in patients with chronic coronary artery disease.
    Murayama S; Yamakado T; Nakano T
    Am J Cardiol; 1997 Jun; 79(12):1685-9. PubMed ID: 9202366
    [TBL] [Abstract][Full Text] [Related]  

  • 42. K+ channel-opening action contributes to the preventive effects of nicorandil on U46619-induced vasoconstriction of canine large coronary arteries in vivo.
    Kamijo T; Iwai T; Haruta K; Takeda K
    Arch Int Pharmacodyn Ther; 1996; 331(3):273-84. PubMed ID: 9124999
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Differential effects of nitrovasodilators, K(+)-channel openers, and nicorandil on large and small coronary arteries in conscious dogs.
    Berdeaux A; Drieu la Rochelle C; Richard V; Giudicelli JF
    J Cardiovasc Pharmacol; 1992; 20 Suppl 3():S17-21. PubMed ID: 1282171
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Ca-antagonist, K-channel-opener in the treatment of patients with congestive heart failure].
    Satoh K
    Nihon Rinsho; 1993 May; 51(5):1293-8. PubMed ID: 8331797
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hemodynamic actions of nicorandil, a new antianginal agent, in the conscious dog.
    Preuss KC; Gross GJ; Brooks HL; Warltier DC
    J Cardiovasc Pharmacol; 1985; 7(4):709-14. PubMed ID: 2410712
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Increased mitochondrial K(ATP) channel activity during chronic myocardial hypoxia: is cardioprotection mediated by improved bioenergetics?
    Eells JT; Henry MM; Gross GJ; Baker JE
    Circ Res; 2000 Nov; 87(10):915-21. PubMed ID: 11073888
    [TBL] [Abstract][Full Text] [Related]  

  • 47. K+ channel opening mediates the vasorelaxant effects of nicorandil in the intact vascular system.
    Cavero I; Pratz J; Mondot S
    Z Kardiol; 1991; 80 Suppl 7():35-41. PubMed ID: 1838848
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Haemodynamic and clinical effects of an intravenous potassium channel opener--a review.
    Kato K
    Eur Heart J; 1993 Jul; 14 Suppl B():40-7. PubMed ID: 8370372
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparative study on the effects of intracoronary nicorandil and nitroglycerin in ischaemic, reperfused porcine hearts.
    Klein HH; Pich S; Lindert-Heimberg S; Schade-Brittinger C; Maisch B; Nebendahl K
    Eur Heart J; 1995 May; 16(5):603-9. PubMed ID: 7588890
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Hemodynamic and neurohumoral responses to intravenous nicorandil in congestive heart failure in humans.
    Giles TD; Pina IL; Quiroz AC; Roffidal L; Zaleski R; Porter RS; Karalis DG; Mohrland JS; Wolf DL; Hearron AE
    J Cardiovasc Pharmacol; 1992 Oct; 20(4):572-8. PubMed ID: 1280713
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Differential effects of endothelin-1 on the vasorelaxant properties of benzopyran and non-benzopyran potassium channel openers.
    Lawson K; Barras M; Zazzi-Sudriez E; Martin DJ; Armstrong JM; Hicks PE
    Br J Pharmacol; 1992 Sep; 107(1):58-65. PubMed ID: 1422579
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Increased tolerance of the chronically hypoxic immature heart to ischemia. Contribution of the KATP channel.
    Baker JE; Curry BD; Olinger GN; Gross GJ
    Circulation; 1997 Mar; 95(5):1278-85. PubMed ID: 9054860
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of a new vasodilator, nicorandil, on exercise-induced impairment of left ventricular function in patients with old myocardial infarction.
    Yokota M; Horisawa T; Iwase M; Miyahara T; Yoshida J; Kamihara S; Noda S; Tsunekawa A; Koide M; Tsuzuki M
    J Cardiovasc Pharmacol; 1987; 10 Suppl 8():S116-22. PubMed ID: 2447418
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Nicorandil reduces myocardial infarct size by opening the K(ATP) channel in rabbits.
    Ohno Y; Minatoguchi S; Uno Y; Kariya T; Arai M; Yamashita K; Fujiwara T; Fujiwara H
    Int J Cardiol; 1997 Dec; 62(3):181-90. PubMed ID: 9476676
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Activation of ATP-dependent K+ channels enhances myocardial protection due to cold high potassium cardioplegia: a force-frequency relationship study.
    Sugimoto S; Puddu PE; Monti F; Dawodu AA; del Monte F; Schiariti M; Campa PP; Marino B
    J Mol Cell Cardiol; 1995 Sep; 27(9):1867-81. PubMed ID: 8523448
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The risk of myocardial stunning is decreased concentration-dependently by KATP channel activation with nicorandil before high K+ cardioplegia.
    Sugimoto S; Iwashiro K; Monti F; Dawodu AA; Schiariti M; Puddu PE
    Int J Cardiol; 1995 Jan; 48(1):11-25. PubMed ID: 7744533
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Therapeutic potential of potassium channel activators in coronary heart disease.
    Haeusler G; Lues I
    Eur Heart J; 1994 Aug; 15 Suppl C():82-8. PubMed ID: 7995277
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Nicorandil, a potent adenosine triphosphate-sensitive potassium-channel opener, ameliorates lung allograft reperfusion injury.
    Yamashita M; Schmid RA; Fujino S; Cooper JD; Patterson GA
    J Thorac Cardiovasc Surg; 1996 Nov; 112(5):1307-14. PubMed ID: 8911328
    [TBL] [Abstract][Full Text] [Related]  

  • 59. KR-31762, a novel KATP channel opener, exerts cardioprotective effects by opening SarcKATP channels in rat models of ischemia/reperfusion-induced heart injury.
    Lee SH; Yang MK; Lim JH; Seo HW; Yi KY; Yoo SE; Lee BH; Won HS; Lee CS; Choi WS; Shin HS
    Arch Pharm Res; 2008 Apr; 31(4):482-9. PubMed ID: 18449506
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Potassium channel opening properties of a novel compound, NIP-121, cromakalim and nicorandil in rat aorta and portal vein.
    Masuda Y; Arakawa C; Yamashita T; Miyajima M; Shigenobu K; Kasuya Y; Tanaka S
    Eur J Pharmacol; 1991 Apr; 195(3):323-31. PubMed ID: 1831135
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.